Resistance to Hsp90 inhibition has become an important concern as several clinical trials are currently in progress for the treatment of cancer. A summary of known mechanisms of resistance to Hsp90 inhibitors is provided, including the recent solution of the Humicola fuscoatra Hsp90 structure, the organism responsible for the biosynthesis of radicicol. Through careful analyses of Hsp90 structures, a plausible mechanism for resistance to Hsp90 inhibitors has been obtained by single mutations about the N-terminal ATP-binding site.
in drug efflux and metabolic alterations were cited as the basis for resistance. Accordingly, Benchekroun and colleagues used photoaffinity-labeling experiments to show that GDA interacts with the P-170 glycoprotein drug efflux pump (P-gp) and that resistant cells expressing this efflux pump exhibited decreased intracellular GDA concentrations ( Figure 2 , panel a). Additional work has confirmed that GDA is both a substrate and an inhibitor of Pgp. Not surprisingly, studies have demonstrated that P-gp inhibition resensitizes cells to GDA, and recent studies by McCollum et al. (6) have reiterated the role of drug efflux pumps for exhibiting resistance to Hsp90 inhibitiors. In addition, they have also demonstrated induction of the stress response as an additional factor in the development of resistance (Figure 2, panel  b) . For example, when GDA-resistant A549 cells were transfected with Hsp27 and/or Hsp70 siRNA, sensistivity to GDA increased 10-fold, whereas pretreatment with the P-gp inhibitor verapamil did not resensitize these cells.
Another hypothesis put forth by Benchekroun's report was that resistance developed from alteration of the cellular reduction potential (Figure 2, panel c) . Subsequent studies identified NAD(P)H/quinone oxidoreductase 1 (NQ01) as the enzyme responsible for reducing the quinone ring of GDA to the higher affinity (~40-fold), hydroquinone. Studies by Gaspar et al. (7) indicated an inverse correlation between NQ01 expression and the IC 50 of 17-AAG, suggesting the mechanism of resistance is a direct consequence of reduction of NQ01 activity. Although some cell lines maintain lower NQ01 activity, results obtained from Gasper and colleagues provided the first example of acquired resistance via this mechanism.
Recent elucidation of Hsp90 cochaperones has led to studies aimed at determining the function of these assistants, as a number of cochaperones are intimately involved with Hsp90 function (8) . For instance, Cox and Miller (9) Fungal secondary metabolites have played an important role in medicinal chemistry, especially in the development of both antimicrobial and antitumor chemotherapies (12) . RDC is isolated from Humicola fuscoatra (13) and has been shown to be a potent inhibitor of Hsp90 in vitro. Not surprisingly, Hsp90 in H. fuscoatra exhibits much lower affinity for RDC than yeast or mammalian homologues because this organism must protect itself from its own biosynthetic products. Isolation and sequencing of the Hsp90 gene from H. fuscoatra revealed two minor differences in the ATP-binding pocket when compared with that of yeast Hsp90. Therefore, the authors sought to incorporate these two mutations into yeast Hsp90, which is normally susceptible to RDC inhibition. Using site-directed mutagenesis, the authors were able to show that mutation of leucine to isoleucine resulted in selective resistance to RDC by yeast Hsp90. When the yeast L34I mutant Hsp90 was constructed, resistance to radicicol was observed, clearly indicating that a single point mutation is sufficient to cause resistance in other organisms. Surprisingly, sensitivity to GDA was unaffected and ATP hydrolysis proceeded at an unaffected rate.
To investigate the diminished RDC inhibitory activity that did not reduce GDA or ATP affinity, Prodromou et al. solved the co-crystal structures of the three ligands bound to mutant Hsp90. Comparative analyses of the structures revealed that the L34I mutation altered the hydration state within the binding pocket by allowing the incorporation of three additional water molecules, resulting in an unfavorable environment for the chlorine substituent of RDC. The change in hydration state, however, did not affect ATP binding due to the absence of hydrophobic groups on the adenine ring. In the case of GDA, the molecule is too large and does not allow for the accommodation of these water molecules, causing GDA's affinity to be unaffected as these water molecules are simply displaced upon binding of the natural product. In a conclusive study, Prodromou and co-workers demonstrated that minor perturbation of the Hsp90 ATP-binding pocket can significantly alter the affinity for specific inhibitory ligands (Figure 2, panel e) .
The studies by Prodromou and colleagues indicate that Hsp90 can retain its chaperone function despite mutations to the ATP-binding pocket. Although these studies provide evolutionary evidence for a mechanism of resistance to Hsp90 inhibition by RDC, research will demonstrate whether pressures can produce such mutations in mammalian cells. In addition, this work begs the question as to how Streptomyces hygroscopicus, the bacteria responsible for GDA biosynthesis, is protected from Hsp90 inhibition, as GDA analogues are further advanced in clinical trials than any other Hsp90 inhibitor. Therefore, these studies reemphasize the importance of understanding the interaction of ligands with Hsp90 and reaffirm the need for new chemical scaffolds that inhibit the Hsp90 protein folding machinery. Mechanisms of resistance to Hsp90 inhibitors: a) drug efflux via P-gp pumps; b) induction of heat shock response; c) decreased NQ01 enzymatic activity, which is responsible for reduction of the GDA quinone to the higher affinity hydroquinone; d) competitive binding of p23/Sba1 to the Hsp90 N-terminus; and e) mutation to the N-terminal binding pocket (L34I), which alters the hydration state.
